One shot of Moderna Inc.'s COVID vaccine generated more than double the antibody by a similar shot of Pfizer Inc. and BioNTech SE, says a study that directly compared the immune responses to the vaccines inferred the result.
According to a report by Bloomberg, the study had subjected almost 2,500 workers at a major Belgium hospital and found that antibody levels among individuals who hadn't been infected before getting both shots of the Moderna vaccine averaged 2,881 units per millilitre compared with 1,108 units per millilitre in a similar group who got both shots of the Pfizer.
The study inferred a higher amount of active ingredients in the Moderna vaccine- 100 micrograms versus 30 micrograms- than in Pfizer-BioNTech. Also, the longer interval could be taken between doses as four weeks for Moderna and three weeks for Pfizer-BioNTech. The result was published on Monday in a letter to the Journal of the American Medical Association.
In another review, from January to July, of people in the Mayo Clinic Health System in the US, it is found that Moderna vaccine serves twofold risk reduction against breakthrough SARS-CoV-2 infections compared to Pfizer. It was reported in a separate study released on August 9, ahead of publication and peer review.